At the ASCO Annual Meeting, Dr. Henry Fung discussed the results of the DREAMM-7 and DREAMM-8 studies on the treatment of relapsed refractory multiple myeloma. Belantamab mafodotin monotherapy did not meet the primary endpoint in a previous study but showed promise in the new analysis. Fung also highlighted the importance of chimeric antigen receptor T-cell therapy for patients with relapsed refractory multiple myeloma. References to the studies were mentioned along with disclosures of Fung’s affiliations with AstraZeneca, Incyte, and Johnson and Johnson. Overall, the studies presented at the meeting showcased potential breakthroughs in multiple myeloma treatment.
Source link
Belantamab mafodotin ‘comeback kid’ for relapsed refractory multiple myeloma
